The trascation allows Pathogenica to combine its next-generation DNA sequencing technology with GenomeQuest’s large-scale whole genome, exome, and microbiome analysis to identify and subselect pathogen genomes in human tissue.
Applications for this research-use only offering will include viral drug resistance studies in pre-clinical or clinical development; co-sequencing of viral drug resistance mutations and human exome samples to predict drug therapy response.
The collaboration also covers custom infectious disease assays combined with deep sequencing and analysis to identify mutant infectious strains in human or mouse samples; and infectious disease biomarker development.
GenomeQuest CEO Richard Resnick said their partnership harnesses the power of next-generation sequencing to examine pathogen-host relationships in pharmaceutical research.
